In the article by Choudhury and Kantoff titled “New Agents in Metastatic Prostate Cancer” published in the November 2012 issue of JNCCN (2012;10:1403-1409) an error occurred in the text on page 1406.
In the last paragraph of the “Immunotherapy” section, the first sentence should have read:
“Another agent currently being studied in a phase III trial (PROSPECT; ClinicalTrials.gov identifier: NCT01322490) is PROSTVAC-VF/TRICOM, a tumor vaccine composed of 2 recombinant viral vectors (a vaccinia-based vector for priming and a fowlpox-vector for subsequent boosting), each encoding transgenes for PSA in addition to 3 immune costimulatory molecules (B7.1, ICAM-1, and LFA-3).
The authors and editorial office apologize for this error. A corrected copy of the article is available online at JNCCN.org.